Ironwood Pharmaceuticals Inc (IRWD) FinancialsIRWDIronwood Pharmaceuticals Inc

Ironwood Pharmaceuticals, Inc. (IRWD) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Human Therapeutics, accounting for 83.8% of total sales, equivalent to $9.19M. Another important revenue stream is Biomanufacturing. Understanding this composition is critical for investors evaluating how IRWD navigates market cycles within the Pharmaceuticals industry.

Evaluating the bottom line, Ironwood Pharmaceuticals, Inc. maintains a gross margin of 100.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 70.16%, while the net margin is 45.37%. These profitability ratios, combined with a Return on Equity (ROE) of N/A, provide a clear picture of how effectively IRWD converts its operational activities into shareholder value.

In the context of the broader market, IRWD competes directly with industry leaders such as OLMA and ZVRA. With a market capitalization of $578.34M, it holds a significant position in the sector. When comparing efficiency, IRWD's gross margin of 100.00% stands against OLMA's N/A and ZVRA's 95.36%. Such benchmarking helps identify whether Ironwood Pharmaceuticals, Inc. is trading at a premium or discount relative to its financial performance.

Ironwood's financials show a gross margin of 100% and a net margin of 45.37% for Q2 2026, indicating strong profitability. However, the company has experienced fluctuations in net income, with a reported net income of $51.29 million in Q2 2026, which is positive.